ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1122

Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities
Abstract Number: 1123

“It’s a Dance Between Managing Both [Diabetes and Osteoarthritis]”: A Qualitative Study Exploring Perspectives of Persons with Knee Osteoarthritis and Type 2 Diabetes Mellitus on the Impact of Osteoarthritis on Diabetes Management and Daily Life
Abstract Number: 1124

Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Abstract Number: 1125

Synovial Perivascular Edema Is Associated with Altered Knee Loading Patterns During Gait in Patients with Medial Compartment-Dominant Knee Osteoarthritis
Abstract Number: 1126

Synovial Cell Dysfunction in Obese Patients May Contribute to Poor Outcomes in Knee Osteoarthritis
Abstract Number: 1127

Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
Abstract Number: 1128

Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
Abstract Number: 1129

Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
Abstract Number: 1130

Osteoarthritis Patients Feel Their Tissue Remodeling
Abstract Number: 1131

Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance
Abstract Number: 1132

Association Between Serum Selenium Level and the Prevalence of Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Abstract Number: 1133

The Relation of Serum Urate to Radiographic Knee Osteoarthritis in 2 Cohorts: The ELSA-Brasil MSK and the Original Cohort of the Framingham Heart Study
Abstract Number: 1134

Osteoarthritis Risk Is Increased in Patients with Atopic Disease
Abstract Number: 1135

Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
Abstract Number: 1136

Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].